



CLINICAL GUIDELINES

CMM-402: Greater Occipital Nerve Block

Version 1.0.2022
Effective August 1, 2022



eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual's Primary Care Physician (PCP) may provide additional insight.

eviCore's Clinical Review Criteria ("CRC") and related content is made available for the limited uses of: reference; and individual use, only limited to facilitating the determination of medically necessary and appropriate clinical treatment by clinicians for specific delegated patients under their care. The CRC and related content is proprietary information of eviCore, and copyrighted to the full extent of the law. Except as expressly permitted, you may not modify, copy, reproduce, republish, upload, post, transmit, hyperlink to or from, or distribute in any way the CRC, nor may you sell, transfer, distribute, assign, lease, reproduce, or otherwise use the CRC in commerce, in a manner that competes with us or infringes upon our rights, or for any public or commercial endeavor without our prior and express written consent.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2022 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

Clinical guidelines for medical necessity review of Comprehensive Musculoskeletal Management Services.

© 2022 eviCore healthcare. All rights reserved.

Definitions

- **Behavioral yellow flags** are defined as an active or history of substance abuse, depression, dissatisfaction with work, job disability, or anxiety diagnosis.
- **Clinically meaningful improvement** is a global assessment showing at least 50% improvement, or pain relief is defined as a two (2) point drop in VAS pain scale where 10 is the worst pain imaginable and 0 is no pain at all.
- **Red flags** indicate comorbidities that require urgent/emergent diagnostic imaging and/or referral for definitive diagnosis and treatment.

General Guidelines

- This guideline only applies to injections of anesthetic only and does not apply to injections of biologics (e.g., platelet rich plasma, stem cells, amniotic fluid, etc.) and/or any other injectates that are not in scope of eviCore's management.
- A complete headache history must be performed which shows that other primary causes of severe headaches have been excluded.

Indications

Initial Greater Occipital Nerve Block

The performance of the initial greater occipital nerve block for occipital neuralgia is considered **medically necessary** when **ALL** of the following are met:

- Clinical findings and imaging studies suggest no other obvious cause of the headache
- Diagnosis of occipital neuralgia as evidenced by both of the following:
 - ◆ Paroxysmal stabbing pain, with or without aching between attacks, in the distribution of the nerve
 - ◆ Tenderness over the affected nerve
- Evidence of a comprehensive headache evaluation with consideration of alternative causes such as any of the following:
 - ◆ Exertional headache
 - ◆ Migraine with or without aura
 - ◆ Medication overuse headache

Second and Subsequent Greater Occipital NerveBlock(s)

The performance of the second and subsequent greater occipital nerve block(s) for recurrent occipital neuralgia are considered **medically necessary** when all of the following are met:

- Clinical findings and imaging studies suggest no other obvious cause of the headache
- Significant improvement after first injection

- Self-care is attempted at headache onset and ineffective and includes both of the following:
 - ◆ Anti-inflammatory medications or muscle relaxants
 - ◆ Rest, massage, or heat
- Confirmed diagnosis of recurrent occipital neuralgia as evidenced by tenderness to palpation over the greater occipital nerve
- Evidence of **BOTH** of the following for patients with chronic pain where there has been continuous opiate usage for 3 months or longer:
 - ◆ Co-management of behavioral health and medical conditions
 - ◆ A plan to address potential opiate overuse or abuse

Non-Indications

Not Medically Necessary

- Greater occipital nerve blocks are considered **not medically necessary** for **ANY** of the following:
 - ◆ When performed in conjunction with additional pain management procedures [cervical facet injections/medial branch blocks (CPT®64490, 64491, and 64492) or trigger point injections (CPT®20552)] planned on the same day
 - ◆ More than 6 greater occipital nerve blocks in the same anatomic areas in the past 12 months
 - ◆ Less than 4 weeks since the last occipital nerve block, cervical trigger point injection, or cervical facet injection/medial branch block

Experimental, Investigational, and/or Unproven (EIU)

- Occipital nerve ablation by any method is considered **experimental, investigational, and/or unproven (EIU)**.
- Use of an injectate other than anesthetic is considered **experimental, investigational, and/or unproven (EIU)**

Procedure (CPT®) Codes

This guideline relates to the CPT® code set below. Codes are displayed for informational purposes only. Any given code's inclusion on this list does not necessarily indicate prior authorization is required. Pre-authorization requirements vary by individual payor.

CPT®	Code Description/Definition
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve

This list may not be all inclusive and is not intended to be used for coding/billing purposes. The final determination of reimbursement for services is the decision of the individual payor (health insurance company, etc.) and is based on the member/patient/client/beneficiary's policy or benefit entitlement structure as well as any third party payor guidelines and/or claims processing rules. Providers are strongly urged to contact each payor for individual requirements if they have not already done so.

References

1. Lennard T., Shin D., Shoulder and chest wall blocks. In: Lennard ed. *Pain procedures in Clinical Practice*. 2nd ed. Hanley & Belfus; 2000:94-95.
2. Silberstein S. Evaluation of the Headache in *Patient. Clinician's Manual on Migraine*. Philadelphia: Current Medicine, Inc.; 2002:Page 9.
3. Balmaceda C., Rossi, J. Detecting Potentially Life-Threatening Headache Syndromes. *J Crit Illn*. 2003;18:23-30.
4. Peters K. S. Secondary headache and head pain emergencies. *Prim Care*. Jun 2004;31(2):381-393, vii.
5. Ashkenazi A., Matro, R., Shaw, J. W., et al. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. *J Neurol Neurosurg Psychiatry*. Apr 2008;79(4):415-417.
6. Krymchantowski A. V., Silva, M. T., Barbosa, J. S., et al. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. *Headache*. Jun 2002;42(6):510-514.
7. Spira P. J., Beran, R. G. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. *Neurology*. Dec 23 2003;61(12):1753-1759.
8. Silberstein S. D., Lipton, R. B., Dodick, D. W., et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. *Headache*. Feb 2007;47(2):170-180.
9. De Felice M., Porreca, F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. *Cephalalgia*. Dec 2009;29(12):1277-1284.
10. Ghiotto N., Sances, G., Galli, F., et al. Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol). *Cephalalgia*. Feb 2009;29(2):233-243.
11. Pageler L., Savidou, I., Limmroth, V. Medication-overuse headache. *Curr Pain Headache Rep*. Dec 2005;9(6):430-435.
12. Lake A. E., 3rd. Medication overuse headache: biobehavioral issues and solutions. *Headache*. Oct 2006;46 Suppl 3:S88-97.
13. Dubois M. Y., Livovich, J., Fletwood, J., et al. Incompetence, drug diversion or pain management? Trying to draw the line. *Pain Med*. Mar 2002;3(1):73-77.
14. Fishbain D. A., Cutler, R. B., Rosomoff, H. L., et al. Is there a relationship between nonorganic physical findings (Waddell signs) and secondary gain/malingering? *Clin J Pain*. Nov-Dec 2004;20(6):399-408.
15. Giordano J., Schatman, M. E. A crisis in chronic pain care: an ethical analysis. Part three: Toward an integrative, multi-disciplinary pain medicine built around the needs of the patient. *Pain Physician*. Nov-Dec 2008;11(6):775-784.
16. Kahan M., Srivastava, A., Wilson, L., et al. Misuse of and dependence on opioids: study of chronic pain patients. *Can Fam Physician*. Sep 2006;52(9):1081-1087.
17. Tacci J. A., Webster, B. S., Hashemi, L., et al. Healthcare utilization and referral patterns in the initial management of new-onset, uncomplicated, low back workers' compensation disability claims. *J Occup Environ Med*. Nov 1998;40(11):958-963.
18. Ferrari A., Leone, S., Tacchi, R., et al. The link between pain patient and analgesic medication is greater in migraine than in rheumatic disease patients. *Cephalalgia*. Jan 2009;29(1):31-37.
19. Bovim G., Fredriksen, T. A., Stolt-Nielsen, A., et al. Neurolysis of the greater occipital nerve in cervicogenic headache. A follow up study. *Headache*. Apr 1992;32(4):175-179.
20. Gille O., Lavignolle, B., Vital, J. M. Surgical treatment of greater occipital neuralgia by neurolysis of the greater occipital nerve and sectioning of the inferior oblique muscle. *Spine (Phila Pa 1976)*. Apr 1 2004;29(7):828-832.
21. First Coast Service Options, Inc. *Local coverage determination (LCD) for peripheral nerve blocks (L33933)*.